Xeris Pharmaceuticals, Inc. Earnings Recaps
Q1 2026
May 8, 2026
Xeris Biopharma's shares rose modestly by 2.5% following Q1 results that showed solid revenue growth driven by Recorlev's strong performance, while Gvoke’s sales were hampered by Medicare-related headwinds, tempering broader enthusiasm.
Key takeaways
- Total revenue grew 38% year-over-year to $83.1 million, with net product revenue up 43% to $82.5 million.
- Recorlev revenue nearly doubled (+95%) to approximately $50 million, driven by record referrals and new patient starts, especially post-Q1 payer resets.
- Gvoke revenue remained flat year-over-year at $20.8 million, impacted by Medicare policy and plan changes that increased out-of-pocket costs and reduced prescription fills.
- Keveyis posted a modest 4% revenue increase to around $12 million, marking its second consecutive quarter of year-over-year growth.
- XP-8121 remains on track for Phase III initiation later this year, leveraging existing commercial and technological capabilities.
Q3 2025
Nov 8, 2025
Xeris Biopharma reported a record-setting Q3 2025 with total product revenue surpassing $74 million, reflecting a 40% year-over-year increase, driven primarily by exceptional growth in its flagship product, RECORLEV.
Key takeaways
- RECORLEV revenue exceeded $37 million, representing a 109% year-over-year growth, supported by a 108% increase in the average number of patients on therapy.
- Total revenue guidance for 2025 has been revised upward to $285-290 million, marking a projected 42% increase at the midpoint.
- Gvoke and KEVEYIS achieved revenues of $25.2 million and $11.9 million, respectively, highlighting steady growth and an expanding patient base.
- The company generated positive cash flow and net income for the first time, showcasing financial scalability and operational strength.
- Strategic expansion initiative underway, nearly doubling sales and patient support teams, aiming to enhance reach and capitalize on market opportunities.